Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30253017 | 1.00 | LOX (0.41) | LOXMBOAT4HTR7HTR1ADRD2 | |
| SCHEMBL5547208 | 0.84 | LOX (0.51) | LOXMBOAT4LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL19786784 | 0.83 | CDK1 (0.33) | LOXHTR7HTR1ADRD2HTR2A | |
| SCHEMBL21245368 | 0.80 | ALOX5 (0.31) | HTR7HTR1ADRD2HTR2AGRM5 | |
| SCHEMBL247456 | 0.78 | CA2 (0.40) | LMNA | |
| SCHEMBL30015590 | 0.78 | CA2 (0.40) | LMNA | |
| SCHEMBL27698215 | 0.78 | CASR (0.37) | HTR7HTR1ADRD2HTR2AGRM5 | |
| SCHEMBL12753748 | 0.78 | ALDH1A1 (0.44) | HTR7HTR1ADRD2HTR2AGRM5 | |
| SCHEMBL3384804 | 0.78 | HTR7 (0.38) | HTR7HTR1ADRD2HTR2ALMNA | |
| Hydrochloric Acid SCHEMBL28231028 | 0.77 | CASR (0.36) | GRM5SMN1; SMN2ALDH1A1PTGS2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382279-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-18 | — | — | US | disclosed |
| EP-4654972-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025095751-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | 현대약품 주식회사 | 2025-05-08 | — | — | WO | disclosed |
| WO-2024159088-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2024-08-02 | — | — | WO | disclosed |
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | disclosed |
| CN-115715288-A | TYK-2 inhibitors | 百济神州有限公司 | 2023-02-24 | — | — | CN | disclosed |
| EP-2291371-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2291371-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-8569292-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569292-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2166846-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009133127-A1 | FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS | MERCK SERONO S.A. (CH) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134392-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134392-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-7612067-B2 | Imidazopyridazine compounds | ELI LILLY AND COMPANY (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1869049-B1 | IMIDAZOPYRIDAZINE COMPOUNDS | LILLY CO ELI (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008156726-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080113978-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| EP-1869049-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006102194-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382279-A1 | COMPOUNDS AND METHODS FOR YAP/TEAD MODULATION AND INDICATIONS THEREFOR | YAP1, YES1, LATS1 | LOX 3672/4885MBOAT4 1325/4885HTR7 2671/4885 |
| US-20240043435-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | LOX 794/4885MBOAT4 3197/4885HTR7 2876/4885 |
| US-20080113978-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | LOX 4172/4885MBOAT4 4123/4885HTR7 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.